View the agenda (as pdf).
Welcome.
Alzheimer’s Association Impact on Global Research: Fueling Discovery at Any Given Moment.
Alzheimer’s Genes to Drugs: Getting the Translation Right
Genetics: Discovery and Risk Scores
Keynote: How Can the Genetic Architecture of AD Inform Disease Mechanism?
APOE4, Ancestry and Clinical Implications
Polygenic Risk Scores for AD: Applications and Optimization for Diverse Populations
Endophenotypes Provide Novel Insight into the Genetics of Alzheimer’s Disease
Human Genetics of Cardiometabolic Disease
Genetics in Drug Discovery: Cognitive Decline in Alzheimer’s Disease
Introduction – Genes and the Environment Across Populations
The Epidemiology and Genetics of AD in Africa
The Comorbid Effects of Cerebrovascular Disease and Genetic Risk in AD
Vascular Risk Factors and Cognitive Decline in Diverse Populations
Modifiable Risk Factors for ADRD
Harmonized Diagnostic Assessment: The Longitudinal Aging Study in India
Sex Differences in Alzheimer’s Disease and Implications for Precision Medicine
Introduction – Biomarkers and Endophenotypes
TREM2 and sTREM2 Signalling in Microglia
Update on Fluid Biomarkers for Neurodegenerative Diseases
Measuring Phosphorylated Tau in Blood as a Biomarker for Alzheimer’s Disease
Imaging and Blood Biomarkers in the Colombian Kindred with Autosomal Dominant AD
Modulation of Protective Microglial Activities in Alzheimer’s Disease
Mechanistic and Dynamic Systems Modeling of Alzheimer’s Disease Across Lifespan
Brain Proteomics Therapeutic Target and Biomarker Discovery
Gut Microbiome Alterations Associated with Alzheimer’s Disease
Introduction – Towards Precision Medicine
Keynote: Multi-Scale Data Integration to Transition Genetic Associations to Therapeutics
Bridging the Gap Between Genetic Research and Prevention
Genetic Counseling and Testing for Alzheimer’s Disease: A View from the Trenches
From Gene Discovery to Clinical Translation: Ethical and Social Implications
Understanding Neuroimmune Biology and Targets in AD Through MODEL-AD and TREAT-AD
Finding Novel Targets Via Antibody Repertoire Analysis of Resilient Patients
Introduction – Therapeutic Targets
Keynote: Using Genomics to Identify Therapeutic Targets for Non-Alzheimer’s Dementias
Targeting Innate Immunity in Alzheimer’s Disease
Genetically-Defined Therapies for Neurodegenerative Disorders
Pathways to Endosome Dysfunction in Alzheimer’s Disease
Omics Analysis to Small Molecule Drug Development: RAB10 and NEK7
Artificial Intelligence Approaches for Discovery in Alzheimer’s Disease Biobanks
Targeting Pre-Symptomatic AD Using Autosomal Dominant AD
Maximizing the Application of Human Genetics for AD Drug Discovery
AAIC Symposium Summary
